Purpose: The long-term effectiveness of topiramate (TPM) was evaluated in c
hildren with West syndrome previously refractory to antiepileptic drug (AED
) therapy.
Methods: Children with infantile spasms who completed a pilot study were el
igible to enter a long-term extension phase in which the dosages of TPM and
other AEDs could be adjusted to optimal response (maximum, 50 mg/kg/day TP
M). The mean duration of long-term therapy was 18 months in the 11 children
who were followed; the mean TPM dosage was 29 mg/kg/day.
Results: Eight (73%) children were continuing TPM therapy at the time data
were analyzed; four (50%) children were spasm free, seven (88%) had experie
nced a greater than or equal to 50% reduction in spasms, and three (38%) we
re able to achieve TPM monotherapy.
Conclusions: TPM was well tolerated in that no patients discontinued becaus
e of adverse events. The response achieved with TPM during the pilot study
was maintained in most children.